These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 3031025)

  • 1. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases.
    Appella E; Robinson EA; Ullrich SJ; Stoppelli MP; Corti A; Cassani G; Blasi F
    J Biol Chem; 1987 Apr; 262(10):4437-40. PubMed ID: 3031025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of human squamous cell carcinoma plasma membrane associated urokinase plasminogen activator by epidermal growth factor.
    Niedbala MJ; Bajetta S; Carbone R; Sartorelli AC
    Cancer Commun; 1990; 2(9):317-24. PubMed ID: 2169831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
    Magdolen V; Rettenberger P; Koppitz M; Goretzki L; Kessler H; Weidle UH; König B; Graeff H; Schmitt M; Wilhelm O
    Eur J Biochem; 1996 May; 237(3):743-51. PubMed ID: 8647121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
    Quax PH; Grimbergen JM; Lansink M; Bakker AH; Blatter MC; Belin D; van Hinsbergh VW; Verheijen JH
    Arterioscler Thromb Vasc Biol; 1998 May; 18(5):693-701. PubMed ID: 9598826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
    Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
    DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.
    Cubellis MV; Andreasen P; Ragno P; Mayer M; Danø K; Blasi F
    Proc Natl Acad Sci U S A; 1989 Jul; 86(13):4828-32. PubMed ID: 2544876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase.
    Rabbani SA; Mazar AP; Bernier SM; Haq M; Bolivar I; Henkin J; Goltzman D
    J Biol Chem; 1992 Jul; 267(20):14151-6. PubMed ID: 1321137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the cellular binding site for the urokinase-type plasminogen activator.
    Estreicher A; Wohlwend A; Belin D; Schleuning WD; Vassalli JD
    J Biol Chem; 1989 Jan; 264(2):1180-9. PubMed ID: 2536017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A monoclonal antibody that recognizes the receptor binding region of human urokinase plasminogen activator.
    Nolli ML; Corti A; Soffientini A; Cassani G
    Thromb Haemost; 1986 Oct; 56(2):214-8. PubMed ID: 2433787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epitope mapping of the anti-urokinase monoclonal antibody 5B4 by isolated domains of urokinase.
    Corti A; Sarubbi E; Soffientini A; Nolli ML; Zanni A; Galimberti M; Parenti F; Cassani G
    Thromb Haemost; 1989 Nov; 62(3):934-9. PubMed ID: 2480654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
    Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
    Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assembly of urokinase receptor-mediated plasminogen activation complexes involves direct, non-active-site interactions between urokinase and plasminogen.
    Ellis V; Whawell SA; Werner F; Deadman JJ
    Biochemistry; 1999 Jan; 38(2):651-9. PubMed ID: 9888805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
    Ploug M; Ostergaard S; Hansen LB; Holm A; Danø K
    Biochemistry; 1998 Mar; 37(11):3612-22. PubMed ID: 9521680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yeast expression and phagemid display of the human urokinase plasminogen activator epidermal growth factor-like domain.
    Stratton-Thomas JR; Min HY; Kaufman SE; Chiu CY; Mullenbach GT; Rosenberg S
    Protein Eng; 1995 May; 8(5):463-70. PubMed ID: 8532668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alveolar macrophage urokinase receptors localize enzyme activity to the cell surface.
    Chapman HA; Bertozzi P; Sailor LZ; Nusrat AR
    Am J Physiol; 1990 Dec; 259(6 Pt 1):L432-8. PubMed ID: 2175557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The receptor for urokinase-plasminogen activator.
    Blasi F; Stoppelli MP; Cubellis MV
    J Cell Biochem; 1986; 32(3):179-86. PubMed ID: 3023408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.
    Ploug M
    Biochemistry; 1998 Nov; 37(47):16494-505. PubMed ID: 9843416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function.
    Fischer K; Lutz V; Wilhelm O; Schmitt M; Graeff H; Heiss P; Nishiguchi T; Harbeck N; Kessler H; Luther T; Magdolen V; Reuning U
    FEBS Lett; 1998 Oct; 438(1-2):101-5. PubMed ID: 9821967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amino-terminal fragment of urokinase-type plasminogen activator inhibits its plasminogen activation.
    Sun Z; Zhang PX; Wang P; Gurewich V; Shen HY; Liu JN
    Thromb Res; 2002 Apr; 106(2):105-11. PubMed ID: 12182908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro anti-proliferative and anti-invasive role of aminoterminal fragment of urokinase-type plasminogen activator on 8701-BC breast cancer cells.
    Luparello C; Del Rosso M
    Eur J Cancer; 1996 Apr; 32A(4):702-7. PubMed ID: 8695276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.